GVHD, ACUTE
Clinical trials for GVHD, ACUTE explained in plain language.
Never miss a new study
Get alerted when new GVHD, ACUTE trials appear
Sign up with your email to follow new studies for GVHD, ACUTE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to stop transplant rejection in blood cancer patients
Disease control Recruiting nowThis study tests whether a new way of giving three drugs (ATG, tacrolimus, and methotrexate) can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers like leukemia. About 29 adults aged 18-60 who have a matched dono…
Matched conditions: GVHD, ACUTE
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
New hope for stem cell transplant patients: drug combo targets deadly GVHD
Disease control Recruiting nowThis study tests whether adding ruxolitinib to standard steroids helps control severe graft-versus-host disease (GVHD) after a stem cell transplant. About 54 adults who develop severe GVHD within 100 days of their first transplant will receive the combination therapy. The goal is…
Matched conditions: GVHD, ACUTE
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
New drug combo aims to tame Graft-Versus-Host disease
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to standard steroids works better than steroids alone for treating grade II acute graft-versus-host disease (GVHD), a common complication after a stem cell transplant. About 168 adults who have had a stem cell transplant for bl…
Matched conditions: GVHD, ACUTE
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Simple blood test may predict deadly transplant complication
Knowledge-focused Recruiting nowThis study looks at whether two blood markers, CXCL9 and EASIX, can predict severe acute graft-versus-host disease (GVHD) before symptoms appear. Researchers will measure these markers in 100 adults receiving a stem cell transplant for blood cancer. The goal is to improve early d…
Matched conditions: GVHD, ACUTE
Sponsor: Henry Ford Health System • Aim: Knowledge-focused
Last updated May 08, 2026 12:04 UTC